On Thursday, the FDA granted full approval to Humacyte, Inc.’s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when ...
The FDA granted a Priority Review in February 2024 and was assigned a PDUFA date of August 10, 2024. ATEV is a bioengineered human tissue designed to be a universally implantable vascular conduit for ...
DURHAM, N.C. - Humacyte, Inc. (NASDAQ:HUMA), a biotechnology firm specializing in bioengineered human tissues with a current market capitalization of $580 million, and Pluristyx, Inc., a provider of ...
DURHAM, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial ...
BRISBANE, Calif. and EDEN PRAIRIE, Minn., April 05, 2023 (GLOBE NEWSWIRE) -- CareDx, Inc. (CDNA) and Miromatrix Medical Inc. (MIRO) -- today announced an exclusive partnership aimed at advancing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback